Antonio Llombart-Cussac

Antonio Llombart-Cussac

UNVERIFIED PROFILE

Are you Antonio Llombart-Cussac?   Register this Author

Register author
Antonio Llombart-Cussac

Antonio Llombart-Cussac

Publications by authors named "Antonio Llombart-Cussac"

Are you Antonio Llombart-Cussac?   Register this Author

53Publications

2080Reads

46Profile Views

Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases.

Histol Histopathol 2017 Sep 1;32(9):909-915. Epub 2016 Dec 1.

Department of Medical Oncology, Hospital Universitari Arnau de Vilanova, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14670/HH-11-849DOI Listing
September 2017

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

J Clin Oncol 2017 Sep 3;35(25):2875-2884. Epub 2017 Jun 3.

George W. Sledge Jr., Stanford University, Stanford; Han Koh, Kaiser Permanente Medical Group, Bellflower, CA; Masakazu Toi, Kyoto University; Kenichi Inoue, Saitama Cancer Center, Saitama; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Patrick Neven, Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium; Joohyuk Sohn, Yonsei Cancer Center, Seoul, Korea; Xavier Pivot, CHU de Besancon Hopital Jean Minjoz, Besancon Cedex; Nawel Bourayou, Eli Lilly, Paris, France; Olga Burdaeva, Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Meena Okera, Adelaide Cancer Centre, Adelaide, Australia; Peter A. Kaufman, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Eva-Maria Grischke, Universitätsklinikum Tübingen Frauenklinik, Tübingen, Germany; Martin Frenzel, Yong Lin, and Ian C. Smith, Eli Lilly, Indianapolis, IN; Susana Barriga, Eli Lilly, Madrid; and Antonio Llombart-Cussac, Hospital Arnau Vilanova, Valencia, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.7585
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.7585DOI Listing
September 2017

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Lancet Oncol 2017 04 24;18(4):545-554. Epub 2017 Feb 24.

Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30021-9DOI Listing
April 2017

Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.

Mol Imaging Biol 2016 08;18(4):545-56

Department of Pathology and Molecular Genetics HUAV, Dept de Ciències Mèdiques Bàsiques, Institut de Recerca Biomedica de Lleida, Univeristy of Lleida, IRBLleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-015-0907-8DOI Listing
August 2016

Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study.

Int J Gynecol Cancer 2016 Jun 2. Epub 2016 Jun 2.

*Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, Lleida; †Hospital Clínico Universitario Clínico San Carlos, Madrid; ‡Fundación Instituto Valenciano de Oncología, Valencia; §Hospital Universitari Valle dHebron, Barcelona; ∥Foundation MD Anderson Cancer Centre Madrid, and Department of Biochemistry, Universidad Autonoma de Madrid (UAM), Instituto de Investigaciones Biomedicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid; and ¶MedSIR ARO, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000715DOI Listing
June 2016

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.

J Clin Oncol 2015 Nov 14;33(32):3781-7. Epub 2015 Sep 14.

Matthew J. Ellis, Baylor College of Medicine, Houston, TX; Antonio Llombart-Cussac, Hospital Arnau de Vilanova, Lérida, Spain; David Feltl, FNsP Ostrava, Ostrava-Poruba, Czech Republic; John A. Dewar, Ninewells Hospital and Medical School, Dundee; Nicola Hewson and Yuri Rukazenkov, AstraZeneca Pharmaceuticals, Macclesfield; John F.R. Robertson, University of Nottingham, Derby, United Kingdom; and Marek Jasiówka, Instytut im Marii Skłodowskiej-Curie, Kraków, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.5831DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737861PMC
November 2015

Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.

Mol Cancer Ther 2014 Apr 21;13(4):776-87. Epub 2014 Jan 21.

Authors' Affiliations: Oncologic Pathology Group, Dept. de Ciències Mèdiques Bàsiques, University of Lleida, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida; and Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0794DOI Listing
April 2014

Reply to A. Ocana et al.

J Clin Oncol 2013 Mar;31(9):1253-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.8271DOI Listing
March 2013

Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.

Arch Bronconeumol 2013 Feb 22;49(2):79-81. Epub 2012 May 22.

Servicio de Oncología Médica, Hospital Universitario Arnau de Vilanova, Lleida, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.arbres.2012.04.003DOI Listing
February 2013

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

Breast Cancer Res Treat 2012 Nov 13;136(2):503-11. Epub 2012 Oct 13.

Division of Breast Surgery, Graduate Entry Medicine & Health School (GEMS), University of Nottingham, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3DT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-2192-4DOI Listing
November 2012

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.

Invest New Drugs 2012 Apr 10;30(2):681-7. Epub 2010 Sep 10.

Medical Oncology Department, St John Hospital, Bécsi út 132, 1032 Budapest, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9538-8DOI Listing
April 2012

Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

Int J Cancer 2012 Feb 18;130(4):967-78. Epub 2011 Jun 18.

Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB-Lleida, Lleida, Spain.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.26096
Publisher Site
http://dx.doi.org/10.1002/ijc.26096DOI Listing
February 2012

Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.

Expert Rev Anticancer Ther 2010 Nov 30;10(11):1825-36. Epub 2010 Sep 30.

Danish Breast Cancer Cooperative Group, Rigshospitalet, Department of Oncology 2501, Blegdamsvej 9, Kobenhavn O 2100, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.10.160DOI Listing
November 2010

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

J Clin Oncol 2009 Sep 24;27(27):4530-5. Epub 2009 Aug 24.

Division of Breast Surgery, University of Nottingham, Nottingham City Hospital, Hucknall Rd, Nottingham, NG5 1PB, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.1136DOI Listing
September 2009

Improving decision-making in early breast cancer: who to treat and how?

Breast Cancer Res Treat 2008 Dec 13;112 Suppl 1:15-24. Epub 2008 Dec 13.

Medical Oncology Service, Hospital Universitario Arnau Vilanova, Av. Alcalde Rovira Roure 80, 25198, Lleida, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-008-0234-8DOI Listing
December 2008

Targeted therapies in gynecologic cancers and melanoma.

Semin Diagn Pathol 2008 Nov;25(4):262-73

Department of Medical Oncology, Dermatology, and Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida-IRB Lleida, Lleida, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semdp.2008.07.008DOI Listing
November 2008

CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.

Mol Cancer Res 2007 Dec;5(12):1285-95

Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park Research Division, 1808 Park Road 1C, P.O. Box 389, Smithville, TX 78957, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-07-0126DOI Listing
December 2007

Synergistic molecular mechanisms in hormone-sensitive breast cancer.

Adv Exp Med Biol 2006 ;587:375-86

Medical Oncology Service, Hospital Universitario Arnau de Vilanova, Lleida, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4020-5133-3_27DOI Listing
January 2007

Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.

Cancer Res 2003 Oct;63(19):6523-31

Duke University Comprehensive Cancer Center, Campus Box 8056, 660 South Euclid, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
October 2003